GLOBUS MEDICAL INC (GMED): M&A transaction — Globus Medical completes acquisition of Nevro Corp. for $5.85/share cash

GLOBUS MEDICAL INC

Completed acquisition of Nevro on April 3, 2025; each Nevro share received $5.85 in cash.
Nevro stock options and RSUs canceled; RSUs converted to cash equal to Merger Consideration.
Acquisition expands Globus's addressable market opportunity to $2 billion in neuromodulation.
Nevro common stock ceased trading on NYSE as of April 3, 2025.
Globus plans to discuss merger benefits during Q1 2025 earnings call in May.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

GLOBUS MEDICAL INC completed an acquisition involving Nevro Corp. for $5.85 per Nevro Share in cash (closed 2025-04-03).

Action: acquisition
Counterparty: Nevro Corp.
Consideration: $5.85 per Nevro Share in cash
Closing: 2025-04-03

Exact text from the filing

or Nevro or by any direct or indirect wholly owned subsidiary of Globus, Merger Sub or Nevro was canceled and extinguished and automatically converted into the right to receive $5.85 per Nevro Share in cash (the “Merger Consideration”), without interest and subject to any applicable withholding taxes. In addition, effective as of immediately prior to the

View on SEC.gov

Browse all m&a transactions →

GLOBUS MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001193125-25-071923

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.